Effective Use of Foreign Clinical Data in Approvals for Medical Devices in Japan

Mari Shirotani, Koji Chiba

Abstract


Initial clinical development of medical devices occurs mainly in the USA and EU, with many medical devices registered in Japan afterwards. As the clinical performance of medical devices is less sensitive to ethnicity than the efficacy and safety of a drug, the performance of such devices can often be evaluated using foreign clinical data. The factors affecting the requirement for Japanese clinical data was investigated in the Japanese approvals of 103 high-risk devices, occurring between April 2005 and March 2015. The requirement for Japanese clinical data was associated with no approval in the USA and EU and the absence of foreign clinical data in the submission (p<0.001). Our results suggest that Japanese clinical data are not an essential requirement when foreign clinical data are included in the Japanese data package for approval, although, for 50% of devices with approval in the USA or EU, Japanese clinical data were still required for the Japanese approval. Reasons for this included the possibility that the performance of the device was sensitive to ethnicity associated with the medical environment, and that the device had been updated from the original one.

Keywords


regulatory science, medical devices, medical device development

Full Text:

PDF

References


The Global Harmonization Task Force. (2006). Principles of Medical Devices Classification. Retrieved from http://www.imdrf.org/docs/ghtf/final/sg1/technical-docs/ghtf-sg1-n15-2006-guidance-classification-060627.pdf

Kramer, D. B., Xu, S., & Kesselheim, A. S. (2012). Regulation of medical devices in the United States and European Union. New England Journal of Medicine, 366, 848-855.

Sorenson, C. & Drummond, M. (2014). Improving medical device regulation: the United States and Europe in perspective. Milbank Quarterly, 92(1), 114-150.

Kramer, D. B., Tan, Y. T., Sato, C., & Kesselheim, A. S. (2014). Ensuring medical device effectiveness and safety: a cross-national comparison of approaches to regulation. Food Drug and Law Journal, 69(1),1-23, i.

Pharmaceuticals and Medical Devices Agency. (n.d.). Information for submission to Japanese authorities (in Japanese). Retrieved January 2017 from https://www.pmda.go.jp/review-services/drug-reviews/about-reviews/devices/0039.html

Evaluation and Licensing Division, Pharmaceutical and Food Safety Bureau, Ministry of Health, Labour and Welfare. (2008). Action program to accelerate reviews of medical devices (in Japanese). Retrieved December 2014 from http://www.mhlw.go.jp/topics/2009/01/tp0105-2.html

Ikeno, F., Ikeda, K., & Uchida, T. (2014). Patient access to medical devices-what about Japan, the second largest medical device market? Cardiovascular Intervention and Therapeutics, 29,1-3.

Pharmaceuticals and Medical Devices Agency. (2014). Information on device lag estimation. (in Japanese). Retrieved January 2016 from https://www.pmda.go.jp/files/000206037.pdf

Pharmaceuticals and Medical Devices Agency. (n.d.). Information on approved products (in Japanese). Retrieved June 2014 from http://www.info.pmda.go.jp/info/syounin_index.html.

U.S. Food and Drug Administration. (n.d.). Drugs@FDA: FDA Approved Drug Products [Drug Database]. Retrieved June 2014 from http://www.accessdata.fda.gov/scripts/cder/daf/

The Ministry of Health, Labour and Welfare. (n.d.). The Article 77-2 of the Pharmaceutical Affairs Law (in Japanese). Retrieved August 2016 from $http://www.mhlw.go.jp/english/policy/health-medical/pharmaceuticals/dl/05.pdf.$.

Ministry of Health, Labour and Welfare. (2009). Overview of Orphan Drug/Medical Device Designation System. Retrieved August 2016 from http://www.mhlw.go.jp/english/policy/health-medical/pharmaceuticals/orphan_drug.html

Evaluation and Licensing Division, Pharmaceutical and Food Safety Bureau, Ministry of Health, Labour, and Welfare. (n.d.). Priority review designation system. Notification no.0227086. (2004) (in Japanese). Retrieved August 2016.

Ministry of Health, Labour and Welfare. (2005). Minutes of the Pharmaceutical Affairs and Food Sanitation Council (in Japanese). Retrieved August 2016 from http://www.mhlw.go.jp/shingi/2005/12/txt/s1202-2.txt

International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. (1997). ICH Harmonized Tripartite Guideline: General considerations for clinical trials E8. Retrieved from http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E8/Step4/E8_Guideline.pdf

U.S. Food and Drug Administration. (2014). Guidance for Industry and Food and Drug Administration Staff. Retrieved from http://www.fda.gov/downloads/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/UCM284443.pdf

U.S. Government Accountability Office. (2009). FDA should take steps to ensure that high-risk device types are approved through the most stringent premarket review process. Retrieved from http://www.gao.gov/assets/290/284882.pdf#search=%27FDA+should+take+steps+to+ensure+that%27